Neurology and psychiatry are areas where diagnosis and treatment are particularly challenging. We are currently witnessing a rapid scientific evolution in the way psychiatric and neurological disorders and the role of centrally-active treatments are regarded. Our psychiatric research has contributed substantially to the current knowledge of the role of serotonin in a wide variety of psychiatric disorders. Our anti-depressant Luvox® was the first SSRI to reach the market in 1983. Another area of our psychiatric research is bifeprunox. The New Drug Application (NDA) for bifeprunox was submitted to the U.S. Food and Drug Administration (FDA) in October 2006 and has recently been officially filed by the FDA.
The recent acquisition of the Parkinson’s medication Duodopa® will be our first commercial contribution to patients suffering from late stage Parkinson’s disease.
Neurology and psychiatry are areas where diagnosis and treatment are particularly challenging. We are currently witnessing a rapid scientific evolution in the way psychiatric and neurological disorders and the role of centrally-active treatments are regarded. Our psychiatric research has contributed substantially to the current knowledge of the role of serotonin in a wide variety of psychiatric disorders. Our anti-depressant Luvox® was the first SSRI to reach the market in 1983. Another area of our psychiatric research is bifeprunox. The New Drug Application (NDA) for bifeprunox was submitted to the U.S. Food and Drug Administration (FDA) in October 2006 and has recently been officially filed by the FDA.
